Phoenix Biotechnology, Inc. (PBI)'s Focus
Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.
PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.
A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.
“The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties". Colapietro Alessandro, Yang Peiying, Rossetti Alessandra, Mancini Andrea, Vitale Flora, Martellucci Stefano, Conway Tara L., Chakraborty Sharmistha, Marampon Francesco, Mattei Vincenzo, Gravina Giovanni Luca, Biordi Assunta Leda, Wei Daoyan, Newman Robert A., Festuccia Claudio. Frontiers in Pharmacology.
PBI sponsored research at the University of Texas at San Antonio has demonstrated that PBI-05204 leads to a marked reduction in neuroinflammtion in brain microglial cells in vitro. Importantly, when fed to mice orally the PBI drug also produces a significant reduction in accumulation of beta-amyloid plaques within the brains of specifically bred transgenic mice that develop Alzheimer’s-like disease. Taken together ,these recent findings suggest that further exploration of the utility of PBI-05204 for neurodegenerative diseases like Alzheimer's is warranted.